Hepatitis C virus (HCV) infection is a major public health concern affecting approximately 3% of the worid's population (1). HCV persists in up to 80% of people infected (2), and chronic infection can lead to progressive liver disease including cirrhosis and hepatocellular carcinoma. HCV-related liver disease is the single leading indication for liver transplantation throughout the worid. Although new therapies have improved the rates of sustained response, a large proportion of patients fails to respond to antiviral treatment or develop significant drug toxicity, thus remaining at risk for disease progression. A subset of individuals is able to mount effective anti-HCV immune responses, and compelling data underscore the importance of the quality and nature of the CTL response in mediating spontaneous and treatment-induced clearance of HCV. An understanding of HCV-host interactions is required to combat this virus and to develop improved therapies. We propose the following inter-related aims:
Specific Aim 1 : To comprehensively investigate the role ofthe T cell immunoglobulin and mucin domain-containing protein-3 (Tim-3)/galectin-9 pathway in conferring protective immunity versus persistence in acute and chronic HCV infection.
Specific Aim 2 : To investigate the effect of manipulating multiple costimulatory/coinhibitory pathways that regulate immune exhaustion and failure of HCV-specific CTLs, define the extent of polyfunctional restoration, and identify the distinct intracellular mechanisms.
Specific Aim 3 : Determine the phenotypic and fimctional aspects of natural killer T (NKT) cells that can be manipulated in order to enhance anti-HCV efficacy.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-BP-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
United States
Zip Code
Goh, Celeste C; Roggerson, Krystal M; Lee, Hai-Chon et al. (2016) Hepatitis C Virus-Induced Myeloid-Derived Suppressor Cells Suppress NK Cell IFN-? Production by Altering Cellular Metabolism via Arginase-1. J Immunol 196:2283-92
Narayanan, Sowmya; Surette, Fionna A; Hahn, Young S (2016) The Immune Landscape in Nonalcoholic Steatohepatitis. Immune Netw 16:147-58
Lim, Sung In; Hahn, Young S; Kwon, Inchan (2015) Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo. J Control Release 207:93-100
Giugliano, Silvia; Kriss, Michael; Golden-Mason, Lucy et al. (2015) Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication. Gastroenterology 148:392-402.e13
Golden-Mason, Lucy; Hahn, Young S; Strong, Michael et al. (2014) Extracellular HCV-core protein induces an immature regulatory phenotype in NK cells: implications for outcome of acute infection. PLoS One 9:e103219
Brownell, Jessica; Bruckner, Jacob; Wagoner, Jessica et al. (2014) Direct, interferon-independent activation of the CXCL10 promoter by NF-?B and interferon regulatory factor 3 during hepatitis C virus infection. J Virol 88:1582-90
Labonte, Adam C; Tosello-Trampont, Annie-Carole; Hahn, Young S (2014) The role of macrophage polarization in infectious and inflammatory diseases. Mol Cells 37:275-85
Lee, Hai-Chon; Narayanan, Sowmya; Park, Sung-Jae et al. (2014) Transcriptional regulation of IFN-? genes in hepatitis C virus-infected hepatocytes via IRF-3·IRF-7·NF-?B complex. J Biol Chem 289:5310-9
Stone, Amy E L; Mitchell, Angela; Brownell, Jessica et al. (2014) Hepatitis C virus core protein inhibits interferon production by a human plasmacytoid dendritic cell line and dysregulates interferon regulatory factor-7 and signal transducer and activator of transcription (STAT) 1 protein expression. PLoS One 9:e95627
Golden-Mason, Lucy; Rosen, Hugo R (2013) Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol Rev 255:68-81

Showing the most recent 10 out of 36 publications